2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
07/11/18Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows Potential for Improvement in Liver Health
Findings from Aarhus University Hospital and the University of Copenhagen Suggest Further Studies on NIAGEN® Should Focus on Therapeutic Potential for Liver Health IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus University Hospital, we... 
Printer Friendly Version
07/09/18TRU NIAGEN® to be featured at the American Association of Naturopathic Physicians Annual Convention and the 2018 Healthy Aging Summit
Participation at two mid-July events will target healthcare practitioners IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its flagship consumer product to help improve the aging process, TRU NIAGEN®, at the American Association of Naturopathic Physicians Annual Convention as well as the 2018 Healthy Aging Summit. The sole active ... 
Printer Friendly Version
06/25/18ChromaDex added to membership of US small-cap Russell 2000® Index
IRVINE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 25, as part of the 2018 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one... 
Printer Friendly Version
06/04/18ChromaDex Appoints Lisa Bratkovich as Chief Marketing Officer
IRVINE, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Lisa Bratkovich as Chief Marketing Officer, effective today. Bratkovich is joining ChromaDex from Direct Upside Group, a direct-to-consumer marketing and customer experience transformation consulting firm, where she has served as CEO and Principal since 2016. Prior to starting her o... 
Printer Friendly Version
05/29/18TRU NIAGEN® to be featured at the American Society for Nutrition's Annual Meeting
ChromaDex Chief Scientific Advisor, Charles Brenner, PhD, to discuss nicotinamide riboside in educational session IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its novel form of vitamin B3, TRU NIAGEN® (Booth #405), at the American Society for Nutrition's Annual Meeting, a gathering of 2500 scientists, healthcare practitioners, res... 
Printer Friendly Version
05/14/18ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board
World-Renowned British Chemist to Assist in Uncovering New Applications for Nicotinamide Riboside and Mitochondrial Health IRVINE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Professor Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of  Cambridge, England, to the Scientific Advisor... 
Printer Friendly Version
05/10/18ChromaDex Corporation Reports First Quarter 2018 Financial Results
- First Quarter 2018 Net Revenues Increased by 95% to $6.6 Million - IRVINE, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today first quarter 2018 financial results. First Quarter 2018 Highlights vs. First Quarter 2017 Net sales up 95%, fueled by growth of TRU NIAGEN®; Gross profit as a percentage of net sales flat at approximately 48%, which include... 
Printer Friendly Version
05/03/18ChromaDex Sets First Quarter 2018 Financial Results on Thursday, May 10, 2018
IRVINE, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, will report financial results for the first quarter of 2018 on Thurs., May 10, 2018. The Company’s financial results for the period will be reported via press release after the close of regular stock market trading hours. The press release will be followed by a conference call at 4:30 p.m. ET / 1:30 p.m. PT with the Comp... 
Printer Friendly Version
05/01/18ChromaDex Remains Confident Amidst Inter Partes Review (IPR) Procedural Changes
SAS Supreme Court decision regarding challenged claims in an IPR has no effect on U.S. Patent 8,197,807 IRVINE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the Patent Trial and Appeal Board (PTAB) has published a Guidance as to how it will apply last week’s Supreme Court of the United States decision (SAS Institute Inc. v Iancu) to trials in pending IPR... 
Printer Friendly Version
04/23/18ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
New Management Structure Further Fuels Strategic Evolution into Consumer-Focused Integrated Nutraceutical Company IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, today announced a new management structure including the appointment of Frank Jaksch to Executive Chairman of the ChromaDex Board of Directors, effective June 22, 2018 after the 2018 Annual Meeting of Stockho... 
Printer Friendly Version
04/05/18TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
Keynote Speaker, Dr. Rudolph E. Tanzi, will sign copies of his new book, “The Healing Self,” at the TRU NIAGEN booth IRVINE, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its cutting-edge form of vitamin B3, TRU NIAGEN, at the American Academy of Anti-Aging Medicine Spring Congress, Booth #1020, taking place April 12-14 in Hollywood, FL.... 
Printer Friendly Version
03/29/18New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
Findings from the University of Colorado, Boulder Study Suggest Future Studies Should Focus on the Therapeutic Potential for Blood Pressure and Vascular Health IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a cutting-edge form of vitamin B3, led by Christopher Martens, PhD and Douglas Seals, PhD, of... 
Printer Friendly Version
03/08/18ChromaDex Corporation Reports 2017 Financial Results   
Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and full year 2017 financial results. Results of operations for the three months ended Dec. 30, 2017 For the three months ended Dec. 30, 2017 (“Q4 2017”), ChromaDex reported net sales from continuing operations of $7.... 
Printer Friendly Version
03/06/18ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
IRVINE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, has been invited to present at the 30th Annual ROTH Capital Partners Conference. The conference is being held on March 11-14, 2018 at The Ritz-Carlton in Dana Point, Calif. ChromaDex management is scheduled to present on Monday, March 12th at 7:30 a.m. Pacific time, with one-on-one meetin... 
Printer Friendly Version
03/02/18ChromaDex Sets Fourth Quarter and Full Year 2017 Conference Call for Thursday, March 8, 2018 at 4:30 p.m. ET
IRVINE, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, will hold a conference call on Thursday, March 8, 2018 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter and full year ended December 30, 2017. The financial results will be reported in a press release after the close of regular stock market trading hours on t... 
Printer Friendly Version
02/20/18Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
New Human Clinical Studies Will Investigate the Role of NIAGEN® Nicotinamide Riboside in Mitochondrial Biogenesis and Systolic Heart Failure IRVINE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that two new collaborative human clinical studies on NIAGEN® Nicotinamide Riboside (NR) have registered and are now underway at the University of Cambridge and ... 
Printer Friendly Version
02/16/18ChromaDex Chairman Stephen Allen Will Retire from Board of Directors
IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age is announcing that on February 13, 2018, Steve R. Allen, the Chairman of the Board, informed the Company that he intends to retire from the Board of Directors at the end of his current term after four years of service.  Accordingly, Mr. Allen will not stand for re-election as a director at Chr... 
Printer Friendly Version
02/12/18ChromaDex Corporation Reports Preliminary 2017 Results   
Fourth Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing selected preliminary fourth quarter and full year 2017 results. Based on preliminary unaudited information, ChromaDex expects to report net revenues for the fourth quarter of 2017 of appr... 
Printer Friendly Version
02/08/18National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease
Results of the Collaborative Study Provide Strong Preclinical Support for Nicotinamide Riboside Research in Alzheimer’s Patients IRVINE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the results from its collaborative research agreement with the NIA and NIH which appear in the Feb. 5, 2018, issue of Proceedings of the National Academy of Sciences (PNAS) ... 
Printer Friendly Version
01/24/18ChromaDex to Present at the 3rd Annual NAD+ Summit
Chief Scientific Advisor of ChromaDex, Dr. Charles Brenner, Headlines Presentation “NAD+: What It Is, How We Lose It, and How To Boost It” IRVINE, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today it will sponsor a gathering of scientific leaders at the 2018 NAD+ Summit on January 26-28, 2018 in San Diego, CA. In collaboration with the Center for Research on A... 
Printer Friendly Version
01/23/18ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary
IRVINE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Mark Friedman as General Counsel and Corporate Secretary, effective immediately. Friedman is joining ChromaDex from Herbalife Nutrition – a global nutrition company that operates in more than 90 countries worldwide – where he served as Executive Vice President and General Counsel ... 
Printer Friendly Version
01/22/18Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)
ChromaDex’s patent portfolio covering its key ingredient in TRU NIAGEN® remains strong IRVINE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Elysium Health, Inc.’s request to invalidate U.S. Patent No. 8,197,807 ("the '807 patent"), covering compositions comprisin... 
Printer Friendly Version
01/08/18ChromaDex and Watsons Expand Partnership with TRU NIAGEN™ Retail Launch in Singapore
After launching in Hong Kong in September, Watsons expands TRU NIAGEN™ retail distribution to Singapore IRVINE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced the launch of TRU NIAGEN™ in Singapore with its retail partner, Watsons. Singapore is the second Asian market for the U.S. made dietary supplement, after Hong Kong. With over 6,000 stores in 11 Asian a... 
Printer Friendly Version